FDA Expands Casgevy to Age 2 on 11-Patient SCD Cohort and Extrapolation
FDA lowered the Casgevy indication to age 2 using small pediatric cohorts plus extrapolation. Evidence rests on single-arm data without new randomized controls in children under 5. Long-term safety and real-world access remain open questions.
Vertex received supplemental approval July 2026 after submitting data from 11 children with SCD and 15 with TDT aged 5 to under 12. All eight evaluable SCD patients met the primary endpoint of no protocol-defined severe VOCs for 12 consecutive months; median transfusion independence in TDT reached 20.1 months. The agency allowed extrapolation to ages 2-4 based on product characteristics and prior adolescent-adult trial results rather than new randomized data in the youngest group.
This marks the first CRISPR-based therapy cleared for pre-school children, shifting intervention before irreversible organ damage documented in natural-history cohorts. Earlier treatment could reduce stroke risk and growth failure, yet the small sample leaves open questions on long-term clonal hematopoiesis and fertility effects that adult follow-up has not fully resolved.
Access barriers remain steep: myeloablative conditioning, specialized centers, and list price above $2 million limit uptake. Payers and state Medicaid programs will face immediate coverage decisions that test whether rare-disease policy can scale to thousands of additional U.S. pediatric patients.
Next studies must deliver multi-year safety registries and comparative effectiveness versus hydroxyurea or transplant to justify broad early use.
Vertex: At least 40% of new U.S. Casgevy starts will be under age 12 by Q4 2028
Sources (3)
- [1]FDA Center for Biologics Evaluation and Research Approval Letter(https://www.fda.gov/media/180123/download)
- [2]NEJM Casgevy Phase 3 Results(https://www.nejm.org/doi/full/10.1056/NEJMoa2216392)
- [3]CLIMB-131 Long-term Follow-up Registry Protocol(https://clinicaltrials.gov/ct2/show/NCT04208529)